These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 29147645)

  • 61. Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis.
    Nguyen NH; Yee BE; Chang C; Jin M; Lutchman G; Lim JK; Nguyen MH
    BMJ Open Gastroenterol; 2016; 3(1):e000066. PubMed ID: 26966549
    [TBL] [Abstract][Full Text] [Related]  

  • 62. High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar.
    Hlaing NKT; Nangia G; Tun KT; Lin S; Maung MZ; Myint KT; Kyaw AMM; Maung ST; Sein Win S; Bwa AH; Loza BL; Win KM; Reddy KR
    J Viral Hepat; 2019 Oct; 26(10):1186-1199. PubMed ID: 31104344
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.
    Gane EJ; Stedman CA; Hyland RH; Ding X; Svarovskaia E; Subramanian GM; Symonds WT; McHutchison JG; Pang PS
    Gastroenterology; 2014 Mar; 146(3):736-743.e1. PubMed ID: 24262278
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis.
    Mangia A; Losappio R; Cenderello G; Potenza D; Mazzola M; De Stefano G; Terreni N; Copetti M; Minerva N; Piazzola V; Bacca D; Palmieri V; Sogari F; Santoro R
    PLoS One; 2018; 13(7):e0200568. PubMed ID: 30063745
    [TBL] [Abstract][Full Text] [Related]  

  • 65. High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naïve and experienced chronic hepatitis C genotype 4: Real world results.
    El Kassas M; Alboraie M; Omar H; El Latif YA; Algaber MA; El Tahan A; El Halwagy H; Afify S; Elserafy M; Elsaeed K; Doss W
    J Med Virol; 2022 Feb; 94(2):667-674. PubMed ID: 30950069
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
    Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
    Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis.
    Suwanthawornkul T; Anothaisintawee T; Sobhonslidsuk A; Thakkinstian A; Teerawattananon Y
    PLoS One; 2015; 10(12):e0145953. PubMed ID: 26720298
    [TBL] [Abstract][Full Text] [Related]  

  • 68. 12 Weeks of a Ribavirin-Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver Transplantation.
    Houssel-Debry P; Coilly A; Fougerou-Leurent C; Jezequel C; Duvoux C; De Ledinghen V; Radenne S; Kamar N; Leroy V; Martino VD; D'Alteroche L; Canva V; Conti F; Dumortier J; Montialoux H; Lebray P; Botta-Fridlund D; Tran A; Moreno C; Silvain C; Besch C; Perre P; Francoz C; Abergel A; Habersetzer F; Debette-Gratien M; Cagnot C; Diallo A; Chevaliez S; Rossignol E; Veislinger A; Duclos-Vallee JC; Pageaux GP;
    Hepatology; 2018 Oct; 68(4):1277-1287. PubMed ID: 29633389
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function.
    Shin HP; Park JA; Burman B; Kozarek RA; Siddique A
    Clin Mol Hepatol; 2017 Dec; 23(4):316-322. PubMed ID: 28827512
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study.
    Iqbal S; Yousuf MH; Yousaf MI
    World J Gastroenterol; 2017 Nov; 23(44):7899-7905. PubMed ID: 29209131
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparison of peg-interferon, ribavirin plus telaprevir vs simeprevir by propensity score matching.
    Fujii H; Nishimura T; Umemura A; Nishikawa T; Yamaguchi K; Moriguchi M; Sumida Y; Mitsuyoshi H; Yokomizo C; Tanaka S; Ishikawa H; Nishioji K; Kimura H; Takami S; Nagao Y; Takeuchi T; Shima T; Sawa Y; Minami M; Yasui K; Itoh Y
    World J Hepatol; 2015 Dec; 7(28):2841-8. PubMed ID: 26668696
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Early Viral Response Predicts the Efficacy of Antiviral Triple Therapy with Simeprevir, Peg-Interferon and Ribavirin in Patients Infected with Hepatitis C Virus Genotype 1.
    Nishida N; Iwanishi M; Minami T; Chishina H; Arizumi T; Takita M; Kitai S; Yada N; Ida H; Hagiwara S; Minami Y; Ueshima K; Sakurai T; Kitano M; Kudo M
    Dig Dis; 2015 Oct; 33(6):708-14. PubMed ID: 26488400
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation.
    Crittenden NE; Buchanan LA; Pinkston CM; Cave B; Barve A; Marsano L; McClain CJ; Jones CM; Marvin MR; Davis EG; Kuns-Adkins CB; Gedaly R; Brock G; Shah MB; Rosenau J; Cave MC
    Liver Transpl; 2016 May; 22(5):635-43. PubMed ID: 26915588
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12.
    Werner CR; Schwarz JM; Egetemeyr DP; Beck R; Malek NP; Lauer UM; Berg CP
    World J Gastroenterol; 2016 Sep; 22(35):8050-9. PubMed ID: 27672299
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis C: an analysis with real world outcomes from a multicentre cohort in Japan.
    Igarashi A; Furusyo N; Ogawa E; Nomura H; Dohmen K; Higashi N; Takahashi K; Kawano A; Azuma K; Satoh T; Nakamuta M; Koyanagi T; Kato M; Shimoda S; Kajiwara E; Hayashi J
    BMJ Open; 2019 Jun; 9(6):e023405. PubMed ID: 31221866
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort.
    Steinebrunner N; Sprinzl MF; Zimmermann T; Wörns MA; Zimmerer T; Galle PR; Stremmel W; Eisenbach C; Stein K; Antoni C; Schattenberg JM; Pathil A
    BMC Gastroenterol; 2015 Aug; 15():97. PubMed ID: 26239732
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study.
    Kang YW; Baek YH; Lee SW; Park SJ; Yoon JS; Yoon KT; Hong Y; Heo NY; Seo KI; Lee SS; Cho HC; Shin JW
    J Korean Med Sci; 2021 May; 36(21):e142. PubMed ID: 34060258
    [TBL] [Abstract][Full Text] [Related]  

  • 78. High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting.
    Han Q; Fan X; Wang X; Wang Y; Deng H; Zhang X; Zhang K; Li N; Liu Z
    Virol J; 2019 Jun; 16(1):74. PubMed ID: 31159813
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Real-world Safety and Effectiveness of 24-week Sofosbuvir and Ribavirin Treatment in Patients Infected with Rare Chronic Hepatitis C Virus Genotypes 3, 4, 5, or 6 in Japan.
    Mita E; Liu LJ; Shing D; Force L; Aoki K; Nakamoto D; Ishizaki A; Konishi H; Mizutani H; Ng LJ
    Intern Med; 2023 May; 62(10):1405-1414. PubMed ID: 36047126
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Two patients treated with simeprevir plus pegylated-interferon and ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation: case report.
    Kawaoka T; Imamura M; Kan H; Fujino H; Fukuhara T; Kobayashi T; Honda Y; Naeshiro N; Hiramatsu A; Tsuge M; Hayes CN; Kawakami Y; Aikata H; Ochi H; Ishiyama K; Tashiro H; Ohdan H; Chayama K
    Transplant Proc; 2015 Apr; 47(3):809-14. PubMed ID: 25891736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.